Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): A case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma

2005 ◽  
Author(s):  
Seiji Nakai ◽  
Tsutomu Masaki ◽  
Takamichi Shintani ◽  
Akihiro Deguchi ◽  
Yasuhiko Kimura ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Monoclonal Antibody ◽  
Liver Cirrhosis ◽  
B Cell ◽  
Liver Dysfunction ◽  
Gastric Lymphoma ◽  
Severe Liver ◽  
Primary Gastric Lymphoma ◽  
Severe Liver Dysfunction ◽  
Large B Cell

scholarly journals A Case Report of a Metastatic Primary Gastric Lymphoma; Diffuse Large B-Cell or Burkitt Lymphoma?

2017 ◽  
Vol 1 (2) ◽  
pp. 32-35
Author(s):  
Hasan Jalaeikhoo ◽  
Mohsen Rajaeinejad ◽  
Manoucher Keyhani ◽  
Mahsa Keshavarz-Fathi
Keyword(s):  
Case Report ◽  
B Cell ◽  
Burkitt Lymphoma ◽  
Gastric Lymphoma ◽  
Primary Gastric Lymphoma ◽  
Large B Cell

scholarly journals A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

2021 ◽  
Author(s):  
Monica Balzarotti ◽  
Massimo Magagnoli ◽  
Miguel Ángel Canales ◽  
Paolo Corradini ◽  
Carlos Grande ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
B Cell ◽  
Dose Escalation ◽  
Cell Lymphoma ◽  
Human Monoclonal Antibody ◽  
B Cell Lymphoma ◽  
Chimeric Mouse ◽  
Open Label ◽  
Large B Cell Lymphoma ◽  
Large B Cell

SummaryBackground BI 836826 is a chimeric mouse–human monoclonal antibody directed against human CD37, a transmembrane protein expressed on mature B lymphocytes. This open-label, phase I dose-escalation trial (NCT02624492) was conducted to determine the maximum tolerated dose (MTD), safety/tolerability, and preliminary efficacy of BI 836826 in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Methods Eligible patients received intravenous infusions of BI 836826 on day 8 and gemcitabine 1000 mg/m2 plus oxaliplatin 100 mg/m2 on day 1, for up to six 14-day treatment cycles. Dose escalation followed the standard 3 + 3 design. Results Of 21 treated patients, 17 had relapsed/refractory DLBCL and four had follicular lymphoma transformed to DLBCL. BI 836826 dosing started at 25 mg and proceeded through 50 mg and 100 mg. Two dose-limiting toxicities (DLTs) occurred during cycle 1, both grade 4 thrombocytopenia lasting > 7 days, affecting 1/6 evaluable patients (17%) in both the 50 mg and 100 mg cohorts. Due to early termination of the study, the MTD was not determined. The most common adverse events related to BI 836826 treatment were neutropenia (52%), thrombocytopenia (48%), and anemia (48%). Eight patients (38%) experienced BI 836826-related infusion-related reactions (two grade 3). Overall objective response rate was 38%, including two patients (10%) with complete remission and six patients (29%) with partial remission. Conclusions BI 836826 in combination with GemOx was generally well tolerated but did not exceed the MTD at doses up to 100 mg given every 14 days.

scholarly journals Severe liver dysfunction complicating course of COVID-19 in the critically ill: multifactorial cause or direct viral effect?

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kevin Roedl ◽  
Dominik Jarczak ◽  
Andreas Drolz ◽  
Dominic Wichmann ◽  
Olaf Boenisch ◽  
...  
Keyword(s):  
Critically Ill ◽  
Liver Dysfunction ◽  
Critically Ill Patients ◽  
Severity Of Illness ◽  
University Hospital ◽  
Severe Liver ◽  
Saps Ii ◽  
Severe Liver Dysfunction ◽  
Global Threat ◽  
The University

Abstract Background SARS-CoV-2 caused a pandemic and global threat for human health. Presence of liver injury was commonly reported in patients with coronavirus disease 2019 (COVID-19). However, reports on severe liver dysfunction (SLD) in critically ill with COVID-19 are lacking. We evaluated the occurrence, clinical characteristics and outcome of SLD in critically ill patients with COVID-19. Methods Clinical course and laboratory was analyzed from all patients with confirmed COVID-19 admitted to ICU of the university hospital. SLD was defined as: bilirubin ≥ 2 mg/dl or elevation of aminotransferase levels (> 20-fold ULN). Results 72 critically ill patients were identified, 22 (31%) patients developed SLD. Presenting characteristics including age, gender, comorbidities as well as clinical presentation regarding COVID-19 overlapped substantially in both groups. Patients with SLD had more severe respiratory failure (paO2/FiO2: 82 (58–114) vs. 117 (83–155); p < 0.05). Thus, required more frequently mechanical ventilation (95% vs. 64%; p < 0.01), rescue therapies (ECMO) (27% vs. 12%; p = 0.106), vasopressor (95% vs. 72%; p < 0.05) and renal replacement therapy (86% vs. 30%; p < 0.001). Severity of illness was significantly higher (SAPS II: 48 (39–52) vs. 40 (32–45); p < 0.01). Patients with SLD and without presented viremic during ICU stay in 68% and 34%, respectively (p = 0.002). Occurrence of SLD was independently associated with presence of viremia [OR 6.359; 95% CI 1.336–30.253; p < 0.05] and severity of illness (SAPS II) [OR 1.078; 95% CI 1.004–1.157; p < 0.05]. Mortality was high in patients with SLD compared to other patients (68% vs. 16%, p < 0.001). After adjustment for confounders, SLD was independently associated with mortality [HR3.347; 95% CI 1.401–7.999; p < 0.01]. Conclusion One-third of critically ill patients with COVID-19 suffer from SLD, which is associated with high mortality. Occurrence of viremia and severity of illness seem to contribute to occurrence of SLD and underline the multifactorial cause.

Purine Analogs for Patients with Non-Hodgkin Lymphoma and Severe Liver Dysfunction

2018 ◽  
Vol 18 ◽  
pp. S291-S292
Author(s):  
Tamer Khashab ◽  
Ashley Manganiello ◽  
Julianne Hibbs ◽  
Thomas Oliver ◽  
Jonathan Doroshow ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Liver Dysfunction ◽  
Severe Liver ◽  
Non Hodgkin Lymphoma ◽  
Purine Analogs ◽  
Severe Liver Dysfunction

scholarly journals Therapeutic Comparison of Chemotherapy and Surgery for Early Stage Diffuse Large B-cell Gastric Lymphoma

2007 ◽  
Vol 48 (6) ◽  
pp. 942 ◽  
Author(s):  
Soo-Jeong Kim ◽  
June-Won Cheong ◽  
Jee Sook Hahn
Keyword(s):  
B Cell ◽  
Early Stage ◽  
Gastric Lymphoma ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document